Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H19F3N4O3 |
Molecular Weight | 456.4172 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(C=CC(F)=C1)C2=NC(NC(CO)CO)=NC3=C2C=CC(=O)N3C4=C(F)C=CC=C4F
InChI
InChIKey=ORVNHOYNEHYKJG-UHFFFAOYSA-N
InChI=1S/C23H19F3N4O3/c1-12-9-13(24)5-6-15(12)20-16-7-8-19(33)30(21-17(25)3-2-4-18(21)26)22(16)29-23(28-20)27-14(10-31)11-32/h2-9,14,31-32H,10-11H2,1H3,(H,27,28,29)
Dilmapimod is a potent p38 mitogen-activated protein kinase (MAPK) inhibitor. It was investigated for its anti-inflammatory effect in non-head injury trauma patients at risk for developing acute respiratory distress syndrome. IL-1β was identified as a gene regulated by dilmapimod that could influence c-reactive protein levels. Dilmapimod had been in phase III clinical trials by GlaxoSmithKline for the treatment of rheumatoid arthritis, neuropathic pain, coronary artery disease (CAD) and chronic obstructive pulmonary disease (COPD). However, these studies were discontinued.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL260 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28004376 |
50.0 µM [IC50] |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21576029
15 mg per day for two weeks
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2149
Created by
admin on Fri Dec 15 15:44:00 GMT 2023 , Edited by admin on Fri Dec 15 15:44:00 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
UU-45
Created by
admin on Fri Dec 15 15:44:00 GMT 2023 , Edited by admin on Fri Dec 15 15:44:00 GMT 2023
|
PRIMARY | |||
|
DB12140
Created by
admin on Fri Dec 15 15:44:00 GMT 2023 , Edited by admin on Fri Dec 15 15:44:00 GMT 2023
|
PRIMARY | |||
|
DTXSID101318338
Created by
admin on Fri Dec 15 15:44:00 GMT 2023 , Edited by admin on Fri Dec 15 15:44:00 GMT 2023
|
PRIMARY | |||
|
444606-18-2
Created by
admin on Fri Dec 15 15:44:00 GMT 2023 , Edited by admin on Fri Dec 15 15:44:00 GMT 2023
|
PRIMARY | |||
|
300000034206
Created by
admin on Fri Dec 15 15:44:00 GMT 2023 , Edited by admin on Fri Dec 15 15:44:00 GMT 2023
|
PRIMARY | |||
|
9119
Created by
admin on Fri Dec 15 15:44:00 GMT 2023 , Edited by admin on Fri Dec 15 15:44:00 GMT 2023
|
PRIMARY | |||
|
Q3238VQW0N
Created by
admin on Fri Dec 15 15:44:00 GMT 2023 , Edited by admin on Fri Dec 15 15:44:00 GMT 2023
|
PRIMARY | |||
|
CHEMBL2103838
Created by
admin on Fri Dec 15 15:44:00 GMT 2023 , Edited by admin on Fri Dec 15 15:44:00 GMT 2023
|
PRIMARY | |||
|
C96531
Created by
admin on Fri Dec 15 15:44:00 GMT 2023 , Edited by admin on Fri Dec 15 15:44:00 GMT 2023
|
PRIMARY | |||
|
10297982
Created by
admin on Fri Dec 15 15:44:00 GMT 2023 , Edited by admin on Fri Dec 15 15:44:00 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)